Green tea as a safe alternative approach for nonalcoholic fatty liver treatment: A systematic review and meta‐analysis of clinical trials

We performed a meta‐analysis to evaluate the efficacy of turmeric/curcumin supplementation on serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in patients with nonalcoholic fatty liver disease (NAFLD). We searched PubMed, Scopus, Cochrane Library, ISI Web of Science, and Google Scholar up to November 20, 2018. Studies that examined the effect of turmeric/curcumin on serum concentrations of ALT and AST among patients with NAFLD were included. The mean difference and standard deviation (SD) of changes in ALT and AST between intervention and control groups were used as effect size for the meta‐analysis. A total of six randomized controlled trials (RCTs) were eligible for meta‐analysis. Results from pooled analysis revealed that turmeric/curcumin supplementation reduced ALT (MD: −7.31 UL/L, 95% CI [−13.16, −1.47], p = 0.014) and AST (MD: −4.68 UL/L, 95% CI [−8.75 −0.60], p = 0.026). When RCTs stratified on the basis of their treatment duration, the significant reduction in serum concentrations of ALT and AST was observed only in studies lasting less than 12 weeks. This review suggests that turmeric/curcumin might have a favorable effect on serum concentrations of ALT and AST in patients with NAFLD. However, further clinical trials are needed to confirm these findings.

Section: Discussioncontrasting

confidence: 99%

Does turmeric/curcumin supplementation improve serum alanine aminotransferase and aspartate aminotransferase levels in patients with nonalcoholic fatty liver disease? A systematic review and meta‐analysis of randomized controlled trials

Goodarzi

Sabzian

Shishehbor

et al. 2019

“…Similar to human studies, investigations on animal species revealed that propolis and its ingredient are safe and do not cause any toxic changes in the liver and kidneys (Celik & Erdogan, ; Jung et al, ; Türkez, Yousef, & Geyikoglu, ). Although propolis, like many alternative remedies, is generally better tolerated than synthetic medications (A. Hadi, Pourmasoumi, Najafgholizadeh, Kafeshani, & Sahebkar, ; Izzo, Hoon‐Kim, Radhakrishnan, & Williamson, ; Mansour‐Ghanaei, Hadi, Pourmasoumi, Joukar, Golpour, & Najafgholizadeh, ), several studies have suggested that propolis had the potential for allergic reactions in certain people. It might cause skin to redden or rashes to develop, itch, and swell.…”

Section: Discussionmentioning

confidence: 99%

The efficacy of propolis on markers of glycemic control in adults with type 2 diabetes mellitus: A systematic review and meta‐analysis

Karimian

Hadi

Pourmasoumi

et al. 2019

Self Cite

Background and Objectives The impetus for the current study was to evaluate the efficacy of propolis supplementation on markers of glycemic status in adults with type 2 diabetes mellitus (T2DM). Methods A comprehensive search was conducted in PubMed, Scopus, Cochrane Library, Web of Science, and Google Scholar up to August 2018, identifying randomized controlled trials investigating the effect of propolis supplementation on glycemic markers in adults with T2DM. Cochrane Collaboration tool was used to evaluate the risk of bias assessment. A random‐effects model was applied in the meta‐analysis to compensate for potential heterogeneity among the included studies. Results Six randomized controlled trials comprising 373 participants were included in the systematic review and meta‐analysis. The results of the meta‐analysis revealed significant reductions in fasting plasma glucose (−13.51 mg/dl; 95% CI [−24.98, −2.04]) and hemoglobin A1C (−0.52%; 95% CI [−0.94, −0.10]) concentrations following propolis supplementation. However, no significant lowering effect was observed in fasting insulin levels (−0.53 pmol/L; 95% CI [−1.69, 0.63]) or homeostasis model assessment of insulin resistance (−0.543; 95% CI [−1.72, 0.64]). Conclusion This systematic review and meta‐analysis suggested that propolis supplementation may be effective in controlling glycemic levels for T2DM patients. Further studies are needed to confirm these results.

“…Green tea extract (GTE) is known as a bona fide herbal therapy for NAFLD and obesity (Mansour‐Ghanaei et al, ; Yang & Hong, ). Most of these health effects are due to the polyphenols and alkaloids.…”

Section: Introductionmentioning

confidence: 99%

Coadministration of epigallocatechin‐3‐gallate (EGCG) and caffeine in low dose ameliorates obesity and nonalcoholic fatty liver disease in obese rats

Yang

Zhu

Zhang

et al. 2019

Epigallocatechin-3-gallate (EGCG) and caffeine in tea exert anti-obesity effects and induces nonalcoholic fatty liver disease (NAFLD) amelioration. However, previous studies usually performed a high-dose EGCG administration, whereas the insecurity was arisen in recent researches. In this study, we treated obese rats with an elaborate dose-40 mg/kg EGCG, 20 mg/kg caffeine, and the coadministration of them as low dose, which were similar to the daily intake; 160 mg/kg EGCG as high dose, which was the maximum safe dose had touched the contentious edge. The results suggested that the coadministration of EGCG and caffeine exerted more remarkable function on suppressing body weight gain, reducing white adipose tissue weight and decreasing the energy intake than single use. This may be due to the variation in serum lipid profile, oxidative stress, and adipose-derived and inflammatory cytokines. The pathological micrographs showed long-term high-fat diets caused severe NAFLD, but it was ameliorated at different levels by all of the administrations. In summary, low dose of EGCG or caffeine only showed a mild effect of anti-obesity and NAFLD amelioration.The coadministration of them could exert a superior curative effect as well as high dose EGCG but no anxiety regarding safety.